NYSE:ADPT

Adeptus Health Stock News

Healthcare > Biotechnology

Buy ADPT

*Your capital is at risk

$22.57

-1.61 (-6.66%)

At Close: Jul 31, 2026

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

07:30am, Tuesday, 07'th Jan 2025

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

04:05pm, Thursday, 02'nd Jan 2025

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

06:30pm, Saturday, 07'th Dec 2024

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

07:30am, Tuesday, 03'rd Dec 2024

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

10:40am, Friday, 29'th Nov 2024

Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Adaptive Biotechnologies: Making Some Progress

10:53am, Tuesday, 26'th Nov 2024

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses, while management has done a good job of reducing quarterly cash burn rates. The company's MRD segment, driv

Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know

11:00am, Friday, 15'th Nov 2024

The consensus price target hints at a 31.4% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

Adaptive Biotechnologies Corporation (ADPT) Q3 2024 Earnings Call Transcript

09:57pm, Thursday, 07'th Nov 2024

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Karina Calzadilla - Head of IR Chad Robins - CEO and Co-Founder Ky

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

07:30pm, Thursday, 07'th Nov 2024

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its

Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

07:15pm, Thursday, 07'th Nov 2024

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago.

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07:30am, Thursday, 07'th Nov 2024

clonoSEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCL Coverage leverages new Medicare episode pricing established based on updated clonoSEQ gapfill rate SEATTLE,

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by